Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Assets (2016 - 2025)

Voyager Therapeutics' Assets history spans 12 years, with the latest figure at $252.3 million for Q4 2025.

  • On a quarterly basis, Assets fell 35.81% to $252.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $252.3 million, a 35.81% decrease, with the full-year FY2025 number at $252.3 million, down 35.81% from a year prior.
  • Assets hit $252.3 million in Q4 2025 for Voyager Therapeutics, down from $288.3 million in the prior quarter.
  • Over the last five years, Assets for VYGR hit a ceiling of $469.6 million in Q1 2024 and a floor of $159.4 million in Q4 2022.
  • Historically, Assets has averaged $290.9 million across 5 years, with a median of $291.5 million in 2023.
  • Biggest five-year swings in Assets: surged 120.44% in 2023 and later crashed 35.81% in 2025.
  • Tracing VYGR's Assets over 5 years: stood at $193.9 million in 2021, then decreased by 17.8% to $159.4 million in 2022, then surged by 120.44% to $351.3 million in 2023, then increased by 11.89% to $393.0 million in 2024, then crashed by 35.81% to $252.3 million in 2025.
  • Business Quant data shows Assets for VYGR at $252.3 million in Q4 2025, $288.3 million in Q3 2025, and $322.1 million in Q2 2025.